PURE Bioscience (OTCMKTS:PURE – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.
PURE Bioscience Stock Up 6.9%
Shares of PURE Bioscience stock opened at $0.07 on Tuesday. The firm has a market cap of $9.10 million, a PE ratio of -2.33 and a beta of 0.16. PURE Bioscience has a 12-month low of $0.04 and a 12-month high of $0.14. The company’s fifty day simple moving average is $0.07 and its two-hundred day simple moving average is $0.06.
About PURE Bioscience
PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.
PURE’s product suite includes concentrate formulations and ready-to-use solutions.
Further Reading
- Five stocks we like better than PURE Bioscience
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
